News - DiagnoCure Inc.reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana.
News - Medicago, a major Canadian biotech company and an international leader in the development and production of plant-based vaccines and therapeutics, is proud to announce that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago’s Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years.
News - The 6th edition of the event Celebrating Partnership was presented by the « Association for the Development of Research and Innovation in Quebec » (ADRIQ) to recognize the achievements of Québec technology collaborations between researchers, entrepreneurs and their partners.
News - B-TEMIA Inc., a market leader in human augmentation, announced the closing of a private placement with a group of Canadian private investors and the Toronto-based private healthcare fund, Epic Capital Management Inc., a boutique investment firm focused on Canadian small and mid-cap securities. This new financing confirms a 60% increase in B-TEMIA's value creation over the last year.
News - TELUS is investing $64 million in new communications infrastructure across the Greater Québec City area this year to connect thousands of homes in Saint-Raymond directly to TELUS’ fibre optic network, enhance wireless capacity and speed, and extend the reach of TELUS Health technology.
News - Nordic Life Science Pipeline is proud to launch the recruitment and testing of volunteers for the double-blind, randomized clinical study (phase II) of SQIN™, the first dermatologic product of its new biocosmeceutical division called NORBIODERM. NORDIC intends to be first in specializing on dermatological products for chronic dry skin conditions (xerosis) typically experienced by individuals with paralysis and/or mobility impairment. Pending upon these results, commercialization of SQIN™ may be announced as early as Q3-2015.
News - handyem Inc., a manufacturer of personal and portable flow cytometers announces the commercial launch of the HPC-150 personal cytometer for life science research, bioprocessing, water quality and many other applications. The HPC-150 flow cytometer from handyem is portable and rugged. Its reliable fiber-optics flow cell eliminates the need for periodic laser alignment and reduces by an order of magnitude the amount of sheath fluid normally required by conventional flow cytometers.
News - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) announces that its common shares began trading under the ticker symbol "OPSSF" on the OTCQX marketplace in the United States, effective today. OTCQX, operated by OTC Markets Group Inc., offers the best informed and most efficient trading for established, global and growth companies. Opsens' shares will continue trading on the TSX Venture Exchange under the ticker symbol "OPS."
News - Case Medical, Inc.® a vertically integrated, product development and manufacturer offering custom designed and modular "do-it-yourself" sterilization systems for the medical industry, and TSO3 Inc (TSX: TSO3), a leading innovator and developer of low-temperature sterilization systems for the healthcare industry, jointly announced today that SteriTite instrument containers and MediTray inserts engineered and manufactured by Case Medical demonstrate excellent compatibility with TSO3's new STERIZONE® VP4 Sterilizer, which is now cleared for sale in the USA.
News - Members of Anges Québec, the Anges Québec Capital Fund and Fier Succès reiterated their confidence in Feldan, a Quebec company that develops cell therapy products, with a new investment of over $1.2M. With this third round of financing completed, the biotechnology company can now rely on a $675K investment from 15 angels, including Jean-Marc Rousseau and Sylvain Chartier, $475K from the Anges Québec Capital Fund and $75K from Fier Succès.